These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 30293498)

  • 1. Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus.
    Bhargava A
    Expert Rev Endocrinol Metab; 2015 Jul; 10(4):353-363. PubMed ID: 30293498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Jentadueto® (linagliptin plus metformin).
    Scheen AJ
    Expert Opin Drug Saf; 2013 Mar; 12(2):275-89. PubMed ID: 23421949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
    Retlich S; Duval V; Graefe-Mody U; Friedrich C; Patel S; Jaehde U; Staab A
    Clin Pharmacokinet; 2015 Jul; 54(7):737-50. PubMed ID: 25637172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
    Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Shimizu M; Kojima Y; Yamamto H; Yasuda D; Sato J; Watada H
    Diabetes Ther; 2019 Feb; 10(1):119-134. PubMed ID: 30483953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
    Koliaki C; Doupis J
    Adv Ther; 2012 Dec; 29(12):993-1004. PubMed ID: 23184570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
    Haak T
    Adv Ther; 2012 Dec; 29(12):1005-15. PubMed ID: 23212658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
    Gallwitz B
    Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
    Grunberger G
    Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.